Later-Line Treatment with Lorlatinib in ALK- and ROS1-Rearrangement-Positive NSCLC: A Retrospective, Multicenter Analysis

In clinical practice, patients with anaplastic lymphoma kinase (ALK)-rearrangement–positive non–small-cell lung cancer commonly receive sequential treatment with ALK tyrosine kinase inhibitors. The third-generation agent lorlatinib has been shown to inhibit a wide range of ALK resistance mutations a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Pharmaceuticals (Basel)
Main Authors: Hochmair, Maximilian J., Fabikan, Hannah, Illini, Oliver, Weinlinger, Christoph, Setinek, Ulrike, Krenbek, Dagmar, Prosch, Helmut, Rauter, Markus, Schumacher, Michael, Wöll, Ewald, Wass, Romana, Brehm, Elmar, Absenger, Gudrun, Bundalo, Tatjana, Errhalt, Peter, Urban, Matthias, Valipour, Arschang
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7694976/
https://ncbi.nlm.nih.gov/pubmed/33171712
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ph13110371
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados